NEW YORK, NY — January 5, 2026 — Leads & Copy —
BNB Plus Corp. (Nasdaq: BNBX) announced it has received a $1.2 million USD order for LineaDNA, the largest in the company’s history. The order is an acceleration of an existing customer’s annual purchasing, consolidating what was planned as a two-year order cycle into a delivery schedule expected to be completed by May 2026.
The order was placed by a global manufacturer of in vitro diagnostics (IVDs) under an existing supply agreement. The company previously announced LineaDNA purchases by this customer, including a $600,000 USD follow-on order in July 2025. This latest order reflects the customer’s decision to accelerate their procurement timeline, resulting in planned delivery within five months rather than the typical two-year cycle.
Inclusive of the recent $1.2 million USD order, the company expects to ship over $1.5 million USD of LineaDNA to customers in the IVD and biotherapeutic markets in the first half of calendar year 2026.
Today’s announcement builds on the company’s continued execution in its fulfillment of large LineaDNA orders. The company recently announced it successfully manufactured and shipped a significant LineaDNA order valued at over $390,000 USD.
The LineaDNA platform is a proprietary, cell-free DNA production system leveraging the company’s expertise in large-scale PCR being commercialized by the company’s LineaRx, Inc. subsidiary. Unlike conventional plasmid-based DNA production methods, the LineaDNA platform produces high-fidelity DNA that is free of adventitious sequences, rapidly scalable, and readily amenable to chemical modification. It can generate DNA from 100 base pairs to 20 kilobases in quantities from milligrams to grams under RUO, GLP, and GMP quality grades.
BNB Plus unlocks access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The company’s differentiated strategy blends DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space. Formerly Applied DNA Sciences, Inc., BNB Plus continues to commercialize the company’s nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
Source: BNB Plus Corp.
